

Chris Zirzow, Vice President of Pharmaceutical Alliances at A-S Medication Solutions, LLC, is the clinical pharmacist who acts as a liaison between our physicians, regulatory, production, sales and customer service departments, so she is always up-to-date on the happenings in the medical industry.

DRUGS GOING OFF PATENT

Starting in 2010, the pharmaceutical industry faces one of the biggest waves of patent expirations ever, affecting dozens of top-selling drugs. Here are some of the drugs facing looming generic competition, and their most recent sales numbers.

| Brand name | Company | Generic name | Uses | Estimated patent expiration | Received FDA approval | Global sales, 3Q 2007 (in millions of dollars) |
|------------------|---------------------------------------|------------------------------------|------------------------------------|-----------------------------|-----------------------|--|
| Crestor | AstraZeneca | Rosuvastatin | Cholesterol | 2012 | 2003 | \$691 |
| Seroquel | AstraZeneca | Quetiapine | Antipsychotic | 2011 | 1997 | \$1,055 |
| Symbicort | AstraZeneca | Budesonide+formoterol | Asthma | 2012 | 2000 | \$371 |
| Plavix | Sanofi-Aventis / Bristol-Myers Squibb | Clopidogrel | Anticoagulant | 2011 | 1998 | \$1,250 |
| Aricept | Pfizer / Eisai | Donepezil HCl | Alzheimer's | 2010 | 1996 | \$100 |
| Lexapro | Forest Laboratories / H. Lundbeck | Escitalopram | Antidepressant | 2012 | 2002 | \$559 |
| Avandia | GlaxoSmithKline | Rosiglitazone | Type 2 diabetes | 2012 | 1999 | \$463 |
| Advair/Seretide | GlaxoSmithKline | Fluticasone, propionate+salmeterol | Asthma | 2010 | 1998/1999 | \$1,721 |
| Levaquin | Johnson & Johnson | Levofloxacin | Antibiotic | 2010 | 1996 | \$366 |
| Zyprexa | Eli Lilly | Olanzapine | Antipsychotic | 2011 | 1996 | \$1,166 |
| Actos | Eli Lilly / Takeda | Pioglitazone | Type 2 diabetes | 2011 | 1999 | \$180 |
| Singulair | Merck | Montelukast | Asthma | 2012 | 1998 | \$1,018 |
| Diovan/Co-Diovan | Novartis | Valsartan+hydrochlorothiazide | Hypertension (high blood pressure) | 2012 | 1996 | \$1,267 |
| Zometa | Novartis | Zoledronic acid | Cancer | 2012 | 2001 | \$318 |
| Lipitor | Pfizer | Atorvastatin | Cholesterol | 2011* | 1996 | \$3,170 |
| Xalatan | Pfizer | Latanaprost | Glaucoma | 2011 | 1995 | \$402 |
| Taxotere | Sanofi-Aventis | Docetaxel | Cancer | 2010 | 1995 | \$694 |
| Aprovel | Sanofi-Aventis / Bristol-Myers Squibb | Irbesartan | Hypertension (high blood pressure) | 2011 | 1998 | \$392 |

*Lipitor may face patent expiration in 2010, not 2011.

Sources: Datamonitor; Dolphin; WSJ.com research